VERV VERVE THERAPEUTICS INC revenue, earnings and financials
For the quarter ended March 31, 2025, VERVE THERAPEUTICS INC reported revenue of n/a, net income of −$31.0M and diluted EPS of −$0.35; for the fiscal year ended December 2024 revenue was n/a.
VERV annual revenue and earnings
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$229M, net income −$199M (margin n/a), EPS −$2.35
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$223M, net income −$200M (margin n/a), EPS −$3.12
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$166M, net income −$157M (margin n/a), EPS −$2.91
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$87.1M, net income −$120M (margin n/a), EPS −$4.48
VERV quarterly revenue and earnings
- Quarter ended Mar 31, 2025: revenue n/a, net income −$31.0M, EPS −$0.35
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$50.0M, EPS −$0.58
- Quarter ended Sep 30, 2024: revenue n/a, net income −$50.1M, EPS −$0.59
- Quarter ended Jun 30, 2024: revenue n/a, net income −$49.8M, EPS −$0.59
- Quarter ended Mar 31, 2024: revenue n/a, net income −$48.7M, EPS −$0.59
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$48.4M, EPS −$0.69
- Quarter ended Sep 30, 2023: revenue n/a, net income −$45.8M, EPS −$0.72
- Quarter ended Jun 30, 2023: revenue n/a, net income −$54.0M, EPS −$0.87
- Quarter ended Mar 31, 2023: revenue n/a, net income −$52.0M, EPS −$0.84
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$41.1M, EPS −$0.66
- Quarter ended Sep 30, 2022: revenue n/a, net income −$45.2M, EPS −$0.79
- Quarter ended Jun 30, 2022: revenue n/a, net income −$40.9M, EPS −$0.84
- Quarter ended Mar 31, 2022: revenue n/a, net income −$30.2M, EPS −$0.62
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$31.3M, EPS $7.64
- Quarter ended Sep 30, 2021: revenue n/a, net income −$22.7M, EPS −$0.47
- Quarter ended Jun 30, 2021: revenue n/a, net income −$53.0M, EPS −$6.66
- Quarter ended Mar 31, 2021: revenue n/a, net income −$13.3M, EPS −$4.99
VERV cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$158M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$150M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$122M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$77.9M, share buybacks n/a
VERV balance sheet
- Mar 31, 2025: cash $96.6M, total assets $614M, total liabilities $141M, shareholders' equity $474M
- Dec 31, 2024: cash $173M, total assets $647M, total liabilities $154M, shareholders' equity $493M
- Sep 30, 2024: cash $159M, total assets $664M, total liabilities $155M, shareholders' equity $509M
- Jun 30, 2024: cash $141M, total assets $701M, total liabilities $155M, shareholders' equity $546M
- Mar 31, 2024: cash $144M, total assets $732M, total liabilities $149M, shareholders' equity $583M
- Dec 31, 2023: cash $206M, total assets $753M, total liabilities $153M, shareholders' equity $600M
- Sep 30, 2023: cash $78.4M, total assets $612M, total liabilities $152M, shareholders' equity $460M
- Jun 30, 2023: cash $70.0M, total assets $589M, total liabilities $124M, shareholders' equity $465M
Is VERV profitable?
No. VERVE THERAPEUTICS INC lost $181M over the last four quarters.
What is VERV's EPS?
Diluted earnings per share over the last four quarters were −$2.11; −$0.35 in the latest quarter.